Li Guangping, Shang Zhenhua, Liu Yihao, Yan Hao, Ou Tongwen
Department of Urology, Xuanwu Hospital Capital Medical University, Beijing, China.
Front Med (Lausanne). 2020 Nov 4;7:576812. doi: 10.3389/fmed.2020.576812. eCollection 2020.
The purpose of this study was to analyze the values of pretreatment serum inflammation markers, lipid, and lipoprotein for predicting the pathological results in men with total prostate-specific antigen between 4 and 10 ng/ml. A total of 611 eligible patients diagnosed with total prostate-specific antigen between 4 and 10 ng/ml and who received a transrectal ultrasound-guided prostate biopsy between January 2014 and December 2019 were included in our study. All the patients were divided into groups according to their pathological results and we collected the data of their pretreatment indicators of the blood routine and biochemistry. The pathological results from prostate biopsies from 160 patients with prostate cancer and 451 patients with benign lesions. Age and total prostate-specific antigen values were significantly higher in patients with prostate cancer than those with benign lesions ( < 0.05). Red blood cell, platelet count, prealbumin, and triglyceride were significantly lower in patients with prostate cancer than those with benign lesions. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte- monocyte ratio, and apolipoprotein B were lower and apolipoprotein A-I was higher in the prostate cancer group than in the benign lesions group but not significantly ( > 0.05). Multivariate logistic regression revealed that age and total prostate-specific antigen could be independent predictors for pathological results (OR, 1.064, 95%CI, 1.031-1.098, < 0.001; OR, 1.232, 95%CI, 1.061-1.429, = 0.006). Higher age and total prostate-specific antigen were closely related to the pathological results. Prospective studies conducted with a large number of patients are needed to evaluate the diagnostic value of non-invasively pretreatment serum inflammation markers and lipoprotein for predicting the pathological results in men with total prostate-specific antigen between 4 and 10 ng/ml.
本研究的目的是分析治疗前血清炎症标志物、脂质和脂蛋白的值，以预测总前列腺特异性抗原在4至10 ng/ml之间的男性患者的病理结果。共有611例符合条件的患者纳入我们的研究，这些患者在2014年1月至2019年12月期间被诊断为总前列腺特异性抗原在4至10 ng/ml之间，并接受了经直肠超声引导下的前列腺活检。所有患者根据其病理结果分组，我们收集了他们治疗前血常规和生化指标的数据。前列腺活检的病理结果显示，160例患者患有前列腺癌，451例患者患有良性病变。前列腺癌患者的年龄和总前列腺特异性抗原值显著高于良性病变患者（<0.05）。前列腺癌患者的红细胞、血小板计数、前白蛋白和甘油三酯显著低于良性病变患者。前列腺癌组的中性粒细胞-淋巴细胞比值、血小板-淋巴细胞比值、淋巴细胞-单核细胞比值和载脂蛋白B较低，而载脂蛋白A-I较高，但差异无统计学意义（>0.05）。多因素logistic回归显示，年龄和总前列腺特异性抗原可能是病理结果的独立预测因素（OR，1.064，95%CI，1.031-1.098，<0.001；OR，1.232，95%CI，1.061-1.429，=0.006）。年龄较大和总前列腺特异性抗原较高与病理结果密切相关。需要对大量患者进行前瞻性研究，以评估非侵入性治疗前血清炎症标志物和脂蛋白对预测总前列腺特异性抗原在4至10 ng/ml之间的男性患者病理结果的诊断价值。
Zotero 插件
